SHANGHAI, March 6, 2026 — A U.S. patient suffering from advanced non‑small cell lung cancer (NSCLC) and Parkinson’s disease has been stabilized by Jiahui International Cancer Center (JICC) through the use of ivonescimab, an innovative immunotherapy that is presently exclusive to China.
The patient, in his seventies, had already gone through all conventional treatment options at MD Anderson Cancer Center in the United States. His physicians suggested ivonescimab, which is the first PD-1/VEGF bispecific antibody approved for solid tumors. Following a video consultation arranged within a week of their first contact in late November, the family selected Jiahui International Cancer Center in Shanghai due to its multidisciplinary capabilities and its Medical Oncology Chief, Dr. XUAN Linli, who received training in the U.S.
Throughout the course of treatment, the patient experienced immune-related side effects that necessitated intensive care unit admission. The cancer center swiftly assembled a team including oncology, neurology, critical care specialists, and guidance from Dr. Zhou Caicun, the principal investigator for ivonescimab. The patient’s condition has subsequently stabilized, with continued treatment aimed at managing the disease.
Jiahui, a tertiary-level international hospital affiliated with Massachusetts General Hospital Cancer Center, offers streamlined services for international patients, covering everything from remote consultations and travel arrangements to regular family communications.
According to the patient’s daughter, “We sincerely appreciate the commitment, empathy, and unwavering dedication of the complete Jiahui staff: physicians, nursing personnel, kitchen and housekeeping employees, the international services team and reception, along with the care assistants. My father particularly wishes to convey his profound gratitude to Ms. Cui, who has provided daily care since his hospitalization. In addition to her meticulous bedside attention, she has given him support, solace, and optimism.”
Innovative oncology breakthroughs from China are opening up alternative treatment possibilities for patients across the globe. JICC is increasingly receiving inquiries and patient referrals from North America, Europe, Asia, and the Middle East, positioning Shanghai as an international center for cutting-edge cancer treatment.
The complete story:
Contact:
International Patient Services
WhatsApp: +852 4619 1904
SOURCE Jiahui International Hospital